Metronidazole oral suspension is a liquid prescription dosage form for patients whose treatment requires an oral liquid rather than a tablet or capsule. The United States has an FDA-approved ready-to-use metronidazole suspension marketed as LIKMEZ, labeled 500 mg/5 mL. This concentration tells you how much metronidazole is present in a specified volume of liquid. It is not a tablet strength, a patient-specific measured dose or proof that every liquid preparation containing metronidazole has the same approval status.
A second category is a compounded oral liquid that may be prepared under applicable compounding rules for an individual patient when medically appropriate. Compounding and FDA approval are different regulatory concepts: an individually compounded suspension is not automatically an FDA-approved generic of LIKMEZ, and products can differ in concentration, excipients, handling, beyond-use dating and measurement. Our LIKMEZ product guide addresses the branded approved suspension; this page compares liquid formulation choices without treating them as interchangeable.
Obtaining any oral metronidazole liquid in the U.S. requires a valid prescription and a clinician's choice of medicine. If tablets cannot be swallowed, the patient should raise that issue before anyone alters a solid tablet or guesses at a liquid volume. The oral metronidazole hub compares liquid medicines with other oral forms, while the pharmacy guide explains legitimate prescription dispensing rather than promising liquid stock.
A ready-to-use oral suspension is a manufactured liquid product whose labeled concentration and instructions are specified by the manufacturer and regulatory record. LIKMEZ is an FDA-approved 500 mg/5 mL oral suspension. A compounded medicine is prepared under a different framework to address a particular clinical need; it is not automatically an approved generic or a standardized replacement for every labeled product.
Tablets and capsules belong to still other oral form categories. A 500 mg tablet contains a fixed mass of drug in one solid unit, while LIKMEZ 500 mg/5 mL identifies a concentration to be measured as a volume. The clinician and pharmacist determine whether a product change is appropriate; patients should not convert medicines themselves.
| Medicine or listing | How strength is expressed | What must be confirmed |
|---|---|---|
| LIKMEZ oral suspension | 500 mg per 5 mL | Approved product label, measured volume and bottle instructions |
| Individually compounded liquid | Concentration depends on preparation | Prescription, compounding details and beyond-use date |
| Generic oral tablet | 250 mg or 500 mg per tablet | Solid dosage form and prescribed tablet count |
| Metronidazole 375 mg capsule | 375 mg per capsule | Correct oral capsule, not liquid volume |
| Vaginal metronidazole gel | Percent concentration for intravaginal use | Not an oral medicine |
LIKMEZ has an FDA-approved oral suspension label specifying 500 mg/5 mL and directions for handling and measurement. That approval is an important distinction from descriptions of unofficial “liquid metronidazole” of unclear provenance. Product labeling supports information about the approved medicine; it should not be interpreted as confirmation that an individual pharmacy currently has the bottle or any particular package size.
The brand is a useful starting point when the prescriber wants a ready-to-use liquid. The actual order should still match the approved formulation, intended route, relevant patient needs and pharmacy's supply. If the product is not available, the pharmacist should coordinate with the prescriber rather than quietly swapping in an unspecified liquid.
The notation 500 mg/5 mL is a concentration, not a direction to take five milliliters. It means the product contains that amount of metronidazole within that volume. The prescribed volume, frequency and duration depend on the clinician's instructions and the patient's clinical situation. A concentration on the bottle is only one part of the information required to use the medicine safely.
A pharmacist can explain how the ordered volume relates to a particular label and how to measure it. Never use a household spoon or convert a tablet prescription to a liquid volume independently. If a new liquid bottle has a different concentration from a previous preparation, the old measuring instructions may be wrong and need explicit review.
LIKMEZ labeling instructs users to shake the bottle well and use a calibrated oral dosing device rather than household teaspoons or tablespoons. This distinction matters because ordinary spoons vary greatly in capacity. A pharmacy may supply or recommend a suitable oral syringe or other calibrated device and should explain how the patient's prescribed volume is measured.
The caregiver should verify the device scale and the prescribed measurement with a pharmacist rather than relying on visual estimates of what constitutes a spoonful. Never assume that a syringe calibrated for another medicine remains appropriate without checking the labeled units and the new prescription.
A compounded preparation may be selected when a clinician and pharmacist determine a patient-specific formulation is needed. Its concentration, vehicle, excipients, instructions, storage conditions and beyond-use date can differ from a manufactured ready-to-use suspension. A compounded liquid is not automatically FDA-approved or considered therapeutically equivalent to LIKMEZ merely because it contains the same active ingredient.
When a pharmacy offers a compounded liquid, ask what concentration it will contain, how it is prepared, what measuring device is supplied and what storage or beyond-use instructions apply. The pharmacist should explain how the preparation is intended to match the authorized prescription. Compounding should not be used as a pretext for unverified product claims or improvised self-treatment.
Difficulty swallowing a tablet or capsule is a clinically relevant concern that should be raised before dispensing. A liquid may be more practical for some patients, but suitability depends on the condition, prescription and actual labeled formulation. A prescriber may need to adjust the prescription to name an appropriate liquid product and concentration rather than assume that any metronidazole liquid can stand in for tablets.
Do not crush 750 mg extended-release tablets or attempt to dissolve other products into a homemade suspension without professional direction. Modified-release products have special restrictions, and ad hoc changes may alter delivery or produce inaccurate dosing. The ER 750 mg product page explains those particular concerns.
A liquid order should identify metronidazole, the oral suspension form, concentration, patient-specific directions and quantity. If it names LIKMEZ, the pharmacy can confirm the approved branded product being dispensed. If it specifies a compounded preparation, the pharmacist should provide its actual concentration and administration details. The patient can compare the final container label against the order and discuss any differences.
Online descriptions that simply say “metronidazole liquid” without a concentration or route are not sufficiently specific. An NDC may identify a manufactured product but not live stock; compounded products may follow a different labeling pathway. Confirm legitimacy, product identity and supply directly with the dispensing pharmacy.
Oral suspension is still systemic metronidazole, with important contraindications, interactions and adverse-effect warnings. The clinician should consider other medicines, prior reactions, relevant medical history and the diagnosed infection. Product-specific labeling for LIKMEZ includes precautions that should be read and discussed rather than replaced with generic assumptions about every metronidazole formulation.
The final bottle label should explain storage and handling conditions and the appropriate use period. Those details are especially important when a liquid is compounded or has a patient-specific beyond-use date. Contact the pharmacist if packaging is damaged, the concentration is unclear or a serious reaction is suspected.
A manufactured ready-to-use suspension and a pharmacy-compounded liquid can be different in ways that are important to the patient after dispensing. A compounded preparation may have a specific beyond-use date, refrigeration or other storage instructions and a concentration determined by the pharmacy's preparation record. Those details should appear in or accompany the dispensed label and should never be inferred from LIKMEZ packaging.
Before leaving the pharmacy, the patient or caregiver can ask for a demonstration of the measuring device, clarification of the storage instructions and the final date through which the preparation should be used. Discarding or replacing expired or compromised medicine should follow pharmacist guidance; a changed appearance or unclear concentration is a reason to ask questions rather than alter the liquid independently.
Confirm that the prescription specifically calls for an oral liquid, not a vaginal gel or dermal solution. Verify the formulation identity, concentration, measured instructions, quantity and measuring device. If the product is compounded, obtain the storage and beyond-use information for that actual preparation rather than assuming LIKMEZ directions apply.
Ask whether the pharmacy can supply the requested liquid and whether a clinician must authorize any substitution. The goal is a correctly measured, appropriate prescription treatment—not a simple conversion from tablets. For broader product context, compare oral tablets and the LIKMEZ label guide.
Yes. LIKMEZ is an FDA-approved metronidazole oral suspension labeled 500 mg/5 mL. Approval does not establish local pharmacy availability.
It is the concentration: 500 mg of metronidazole in five milliliters of suspension. It does not tell an individual patient what volume or regimen to take.
No. Both contain metronidazole, but one is a manufactured oral liquid expressed as a concentration and the other is a solid oral tablet with drug amount per unit.
The LIKMEZ label instructs users to shake the suspension well before measuring the prescribed dose. Ask the pharmacist about the actual product instructions.
A calibrated oral dosing device should be used instead of household teaspoons or tablespoons, which do not provide reliable measurement.
Compounded preparations are not automatically FDA-approved medicines or generic equivalents to LIKMEZ. Ask the pharmacy about their specific formulation, concentration and handling.
Do not alter tablets or prepare a homemade suspension without professional guidance. Extended-release tablets in particular have restrictions on crushing or splitting.
No. Oral suspension is taken by mouth as prescribed. Vaginal metronidazole gels have distinct labeling and should not be interchanged.
No. Concentrations can differ, particularly in compounded preparations. Every prescription and measuring device must be checked against the actual bottle.
Check oral route, product name, concentration, quantity, prescribed volume directions, suitable measuring device and storage information with the pharmacist.